Boehringer Ingelheim Pharmaceuticals, with U.S. headquarters in Ridgefield, announced Thursday that Gilotrif oral tablets will become commercially available in the U.S. the week of Sept. 2.
This medication is used to treat lung cancer patients with specific mutations. An estimated 15 percent of Caucasians and 40 percent of Asians have this mutation.
Until Gilotrif becomes commercially available, patients who need the medication can enroll in the Boehringer expanded access program. Boehringer Ingelheim will provide support to healthcare professionals and patients to help with the transition process once the product becomes accessible.
This update came from Kristin Banta at the Hartford Business Journal